Ricoh USA Spins Off Healthcare 3D Printing Division as Independent Company Myrava

Ricoh USA has sold its healthcare 3D printing division to the executive who ran it for years. Gary Turner, formerly VP and General Manager of Additive Manufacturing at Ricoh USA, has rebranded the business as Myrava and taken it independent.

The deal gives Turner full control over a unit that already holds multiple FDA clearances for patient-specific anatomical models and has built real relationships with hospitals and point-of-care providers.

What Myrava Does

Under Turner's leadership, Ricoh 3D for Healthcare focused on producing patient-specific anatomical models and devices at the point of care. In 2024 the division opened an Additive Manufacturing Center of Excellence at North Carolina State University, placing it in one of the most active medical innovation clusters in the United States.

Myrava's website signals the same focus: co-located services that put 3D printing capability directly inside healthcare facilities. That model requires long-term relationships with hospital staff, regulatory expertise, and a track record of delivering consistent results.

Why Ricoh Sold It

Ricoh USA said in a statement that patient-specific medical devices require specialized capabilities that sit outside its broader business priorities. The company wants to concentrate on process automation, workplace services, and cost reduction for healthcare providers. Myrava's work, by contrast, needs dedicated investment in a narrow clinical market.

Bob Lamendola, Chief Digital Services and Delivery Officer at Ricoh USA, framed the sale as a clean split: Myrava gets dedicated ownership, while Ricoh stays focused on the services it can deliver at scale.

Why This Is a Good Outcome

Turner and his team spent a year operating Ricoh 3D for Healthcare as a standalone LLC before the sale. That transition period meant continuity was already in place when the deal closed.

For an industry built on long-term customer trust, that continuity matters. Hospitals do not switch 3D printing partners lightly, especially when FDA compliance is involved. Myrava keeps the team, the clearances, and the customer relationships intact.

The medical 3D printing segment remains one of additive manufacturing's most valuable markets. Patient-specific solutions are not a fad, and the United States is still the dominant force in medical device manufacturing worldwide. Myrava is now positioned to grow in that market without the overhead of a large diversified parent company.

A Template Worth Watching

Ricoh USA is an American subsidiary of a Japanese parent, and Japanese corporations have a long history of internal spin-outs that give specialized divisions room to grow while keeping them connected to a stable owner. American companies rarely follow that pattern, partly because their investors usually prefer short-term returns.

If Myrava succeeds as an independent company, it could become a reference point for other diversified manufacturers with niche 3D printing divisions. Selling to the person who built the business is not the easiest path, but it may be the right one.